Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma
Exelixis, Inc. (NASDAQ: EXEL) today reported positive preliminary data from the cohort of hepatocellular carcinoma patients participating in the ongoing phase 2 randomized discontinuation trial of cabozantinib. Allan Lee Cohn, M.D., Medical Director of Research at the Rocky Mountain Cancer Centers, will present the data today at 11:45 a.m. PST as part of the 2012 Gastrointestinal Cancers Symposium. The meeting is taking place in San Francisco, California.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.